Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6

Jiang, Li; Zhao, Xinwei; Mao, Yinling; Wang, Junfeng; Zheng, Huijun; You, Qingshan

doi:10.1186/s13046-019-1428-0

Cited by 104 publications

(74 citation statements)

References 45 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LncRNAs, which are encoded by an unstudied region of the human genome, may contain cancer-missing drivers and have attracted attention in recent years as potentially important regulators of carcinogenesis and cancer development. Increasing evidence has indicated that lncR-NAs play an important role in various human diseases, especially in malignant tumors [21][22][23][24]. Antisense long non-coding RNAs, such as TTN-AS1, IDH1-AS1 and AFAP-AS1, have been reported in tumors and closely related to the prognosis, development, invasion and metastasis of tumors [25][26][27].…”

Section: Discussionmentioning

confidence: 99%

The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis

Yang¹,

Wang²,

Zhong³

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: Family with sequence similarity 83 member H antisense RNA 1 (FAM83H-AS1) is a novel long noncoding RNA. Increasing studies have reported that FAM83H-AS1 is abnormally expressed in a variety of tumors and is associated with poor outcome. However, the clinical prognostic significance of lncRNA FAM83H-AS1 in tumors is not completely known. Methods:In this meta-analysis, literature was collected up until February 5, 2020 through multifarious retrieval strategies by searching through electronic databases of PubMed, Cochrane Library, EMBASE, Medline, Web of Science, CNKI, Weipu, and Wanfang. A total of 14 studies that met the inclusion criteria with relevant clinical data and prognostic information were included in the meta-analysis. Results:The combined results revealed that high expression of FAM83H-AS1 was associated with poor overall survival (OS) (HR = 1.63, 95% CI 1.24-2.14, P = 0.0004) in a variety of cancers. Additionally, upregulated FAM83H-AS1 expression was significantly correlated with tumor TNM stage (III/IV vs. I/II, OR = 2.40, 95% CI 1.36-4.23, P = 0.003) and lymph node metastasis (positive vs. negative, OR = 1.70, 95% CI 1.14-2.52, P = 0.008) in patients with cancer. Conclusions:Our results of this meta-analysis indicated that elevated FAM83H-AS1 expression could predict poor prognosis in patients with cancer and suggested that FAM83H-AS1 might serve as a novel biomarker for cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis

Yang¹,

Wang²,

Zhong³

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“… 32 The dysregulation of the JAK/STAT signaling pathway has been implicated in the initiation and progression of various cancers, including EC. 33 - 35 Yu et al found that the JAK-STAT pathway was significantly reduced by unbiased RNA sequencing in RNF168-depleted EC cell. Silence of RNF168 reduces JAK-STAT target genes, such as IRF1, IRF9, and IFITM1.…”

Section: Discussionmentioning

confidence: 99%

Multiomic Analysis of Methylation and Transcriptome Reveals a Novel Signature in Esophageal Cancer

Jin¹,

Miao²

2020

Dose-Response

View full text Add to dashboard Cite

Background: Epigenetic alterations have been shown to lead to human carcinogenesis. The aim of this study was to perform an integrative analysis to develop an epigenetic signature to predict overall survival (OS) of esophageal cancer. Methods: DNA methylation and messenger RNA expression data of esophageal cancer samples were downloaded from The Cancer Genome Atlas database and were incorporated and analyzed using an R package MethylMix. Functional enrichment analysis of the methylation-related differentially expressed genes (DEGs) was performed. Epigenetic signature and nomogram associated with the OS of esophageal cancer were established by the multivariate Cox model. Results: A total of 71 methylation-related DEGs were identified. Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed that these genes were involved in the biological process related to the initiation and progression of esophageal cancer. Two-gene (FAM24B and FAM200A) risk signature for OS was developed by multivariate Cox analysis, of which had high accuracy. The signature is independent of clinicopathological variables and indicated better predictive power than other clinicopathological variables. Moreover, we developed a novel prognostic nomogram based on risk score and 3 clinicopathological factors. Conclusions: Our study indicated possible methylation-related DEGs and established an epigenetic signature, which may provide novel insights for understanding the pathogenesis of esophageal cancer.

show abstract

“…In recent years, a number of studies have demonstrated that dysregulated lncRNAs play an important role in the carcinogenesis, development and metastasis of different types of tumor (33)(34)(35). A number of lncRNAs have been reported to be associated with the recurrence, metastasis and resistance to adjuvant therapy of patients with BC (36,37).…”

Section: Discussionmentioning

confidence: 99%

Development of a nine‑lncRNA signature as a novel prognostic marker of estrogen receptor‑negative breast cancer

Wang

Liu

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have been demonstrated to be aberrantly expressed in several types of tumor, and dysregulated lncRNAs are suggested to play a prognostic role in breast cancer (BC). Estrogen receptor (ER) status is a prognostic factor in patients with ER-negative BC, which is associated with poor prognosis. Thus, the present study developed a prognostic lncRNA signature specifically for ER-negative BC, in order to predict the risk of post-surgery relapse and improve patient prognosis. A gene expression profile containing 1,631 lncRNAs was obtained by investigating and integrating publicly available cohorts of BC. Subsequently, a nine-lncRNA signature was developed and validated in two independent cohorts via the Cox regression model. Using the nine-lncRNA signature, patients in the discovery cohort were divided into high-and low-risk groups, with significantly different disease-free survival [DFS; hazard ratio (HR)=2.718, 95% confidence interval (CI)=2.115-3.494, P<0.0001]. Receiver operating characteristic curve analyses demonstrated that the area under the curve reached 0.908. Similar results were obtained in the two independent cohorts (HR=1.499, 95% CI=0.950-2.365, P=0.04; HR=1.262, 95% CI=1.056-1.510, P=0.01), respectively. Furthermore, the nine lncRNAs were demonstrated to play important roles in the cell invasion and metastasis of different types of tumor. The differentially expressed genes (DEGs) identified between the high-and low-risk groups were consistently high in the discovery and validation cohorts. Functional analysis indicated that these DEGs, as well as genes co-expressed with the nine lncRNAs, were involved in cancer-associated signaling pathways, all of which provide further evidence for the predictive ability of the nine-lncRNA signature. Overall, the present study developed a novel prognostic biomarker for ER-negative BC.

show abstract

Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6

Cited by 104 publications

References 45 publications

The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis

The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis

Multiomic Analysis of Methylation and Transcriptome Reveals a Novel Signature in Esophageal Cancer

Development of a nine‑lncRNA signature as a novel prognostic marker of estrogen receptor‑negative breast cancer

Contact Info

Product

Resources

About